# Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

> **NCT06695117** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 980 (actual)

## Conditions studied

- COVID-19 Immunization
- Influenza Immunization

## Interventions

- **BIOLOGICAL:** IIV-HD
- **BIOLOGICAL:** rC19 (dose 1)
- **BIOLOGICAL:** IIV-HD + rC19 (dose 1)
- **BIOLOGICAL:** IIV-HD + rC19 (dose 2)
- **BIOLOGICAL:** IIV-HD + rC19 (dose 3)
- **BIOLOGICAL:** IIV-HD + rC19 (dose 4)
- **OTHER:** Placebo (0.9% NaCl)

## Key facts

- **NCT ID:** NCT06695117
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-19
- **Primary completion:** 2026-04-16
- **Final completion:** 2026-04-16
- **Target enrollment:** 980 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06695117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06695117, "Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06695117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*